Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Sgr-1505 Is a Potent MALT1 Protease Inhibitor with a Potential Best-in-Class Profile

Wu Yin, Min Ye, Netonia Marshall, Joanne BL Tan, Evan Paull, Zhe Nie, MIchael Trzoss, Goran Krilov, Shulu Feng, Robert Pelletier, Jeff Bell, Peter Skrdla, David Calkins, MaryBeth Grimes, D. Hamish Wright, Karen Akinsanya

Blood (2023) 142 (Supplement 1): 2997.

https://doi.org/10.1182/blood-2023-190985

Published: 2023

Journal Articles

Inhibition of CDC7 with Sgr-2921 in AML Models Results in Enhanced DNA Damage and Anti-Leukemic Activity As Monotherapy and in Combination with Standard of Care Agents

Lyuben Tsvetkov, Janét Pittsenbarger, Christian Atsriku, Paul Devine, Karen Dingley, Adam Levinson, Sayan Mondal, Joseph Piccotti, Roman Shimanovich, Lin Tang, Daniel Weiss, Jacky Woo, Min Ye, Wu Yin, Karen Akinsanya, Wayne Tang, Hamish Wright, Elie Traer, Kristian Jensen

Blood (2022) 140 (Supplement 1): 5961–5962.

https://doi.org/10.1182/blood-2022-167239

Published: 2022

Journal Articles

Characterization of Potent Paracaspase MALT1 Inhibitors for Hematological Malignancies

Blood (2021) 138 (Supplement 1): 1187.

https://doi.org/10.1182/blood-2021-153159

Published: 2021

Journal Articles

LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML

Monica Cusan, Sheng F. Cai, Helai P. Mohammad, Andrei Krivtsov, Alan Chramiec, Evangelia Loizou, Matthew D. Witkin, Kimberly N. Smitheman, Daniel G. Tenen, Min Ye, Britta Will, Ulrich Steidl, Ryan G. Kruger, Ross L. Levine, Hugh Y. Rienhoff, Jr, Richard P. Koche, Scott A. Armstrong

Blood (2018) 131 (15): 1730–1742.

https://doi.org/10.1182/blood-2017-09-807024

Published: 2018

Includes: Supplemental data

Journal Articles

LSD1 Inhibition Exerts Its Anti-Leukemic Effect By Recommissioning PU.1- and C/Ebpα-Dependent Enhancers in AML

Monica Cusan, MD, Sheng Cai, MD PhD, Helai P Mohammad, PhD, Andrei V. Krivtsov, PhD, Alan Chramiec, Evangelia Loizou, Daniel G. Tenen, MD, Min Ye, PhD, Britta Will, PhD, Ulrich G. Steidl, MDPhD, Ryan G. Kruger, PhD, Richard Koche, PhD, Scott Armstrong, MD PhD

Blood (2017) 130 (Supplement 1): 242.

https://doi.org/10.1182/blood.V130.Suppl_1.242.242

Published: 2017

Journal Articles

Sox4 Is Required for the Formation and Maintenance of Multipotent Progenitors

Hong Zhang, PhD, Min Ye, PhD, Robert S. Welner, PhD, Daniel G. Tenen, MD

Blood (2014) 124 (21): 1577.

https://doi.org/10.1182/blood.V124.21.1577.1577

Published: 2014

Journal Articles

The Runx-PU.1 pathway preserves normal and AML/ETO9a leukemic stem cells

Philipp B. Staber, Pu Zhang, Min Ye, Robert S. Welner, Elena Levantini, Annalisa Di Ruscio, Alexander K. Ebralidze, Christian Bach, Hong Zhang, Junyan Zhang, Katrina Vanura, Ruud Delwel, Henry Yang, Gang Huang, Daniel G. Tenen

Blood (2014) 124 (15): 2391–2399.

https://doi.org/10.1182/blood-2014-01-550855

Published: 2014

Includes: Supplemental data

Journal Articles

C/EBPα is required for development of dendritic cell progenitors

Robert S. Welner, Deepak Bararia, Giovanni Amabile, Akos Czibere, Touati Benoukraf, Christian Bach, K. Disnika Senali Abayratna Wansa, Min Ye, Hong Zhang, Tadafumi Iino, Christopher J. Hetherington, Koichi Akashi, Daniel G. Tenen

Blood (2013) 121 (20): 4073–4081.

https://doi.org/10.1182/blood-2012-10-463448

Published: 2013

Includes: Supplemental data

Journal Articles

In vivo generation of transplantable human hematopoietic cells from induced pluripotent stem cells

Giovanni Amabile, Robert S. Welner, Cesar Nombela-Arrieta, Anna Morena D'Alise, Annalisa Di Ruscio, Alexander K. Ebralidze, Yevgenya Kraytsberg, Min Ye, Olivier Kocher, Donna S. Neuberg, Konstantin Khrapko, Leslie E. Silberstein, Daniel G. Tenen

Blood (2013) 121 (8): 1255–1264.

https://doi.org/10.1182/blood-2012-06-434407

Published: 2013

Includes: Supplemental data

Journal Articles

Identification of Sox4 As Key Oncogene in Leukemias with Mutated or Silenced C/EBPα

Hong Zhang, PhD, Min Ye, PhD, Meritxell Alberich-Jordà, PhD, Giovanni Amabile, PhD, Philipp B. Staber, M.D., Peter J. M. Valk, PhD, Ruud Delwel, PhD, Véronique Lefebvre, PhD, Constanze Bonifer, PhD, Daniel G. Tenen, MD

Blood (2012) 120 (21): 114.

https://doi.org/10.1182/blood.V120.21.114.114

Published: 2012

Journal Articles

Runx1 Induced Chromatin Folding of the PU.1 Gene Locus Is Necessary for Adult Long-Term Hematopoietic Stem Cell Maintenance

Philipp B. Staber, M.D., Pu Zhang, M.D., Min Ye, PhD, Gang Huang, Annalisa Di Ruscio, MD, Alexander K Ebralidze, PhD, Daniel G. Tenen

Blood (2011) 118 (21): 2364.

https://doi.org/10.1182/blood.V118.21.2364.2364

Published: 2011

Journal Articles

PU.1 Is a Downstream Target of C/EBPα in Normal Hematopoiesis and Acute Myeloid Leukemia

Christian Bach, Ph.D., Philipp B. Staber, M.D., Min Ye, Ph.D., Pu Zhang, M.D., Alan D. Friedman, M.D., Ruud Delwel, Ph.D., Daniel G. Tenen

Blood (2011) 118 (21): 1353.

https://doi.org/10.1182/blood.V118.21.1353.1353

Published: 2011

Journal Articles

Increasing C/Ebpα Expression Regulates the Transition of Hematopoietic Stem Cells During Development.

Min Ye, PhD, Hong Zhang, PhD, Pu Zhang, MD, Daniel G. Tenen, MD

Blood (2009) 114 (22): 1506.

https://doi.org/10.1182/blood.V114.22.1506.1506

Published: 2009

Journal Articles

Autoregulation of the Transcription Factor PU.1 Via Its Evolutionarily Conserved Upstream Regulatory Element Is Critical in Adult Mouse Hematopoiesis.

Philipp B. Staber, M.D., Pu Zhang, M.D., Min Ye, Ph.D., Gang Huang, Ph.D., Boris Bartholdy, Ph.D., Annalisa DiRuscio, M.D., Alexander K. Ebralidze, Ph.D., Daniel G. Tenen, M.D.

Blood (2009) 114 (22): 1468.

https://doi.org/10.1182/blood.V114.22.1468.1468

Published: 2009

Journal Articles

T to Myeloid Lineage Reprogramming by the Synergistic Action of C/EBP and PU.1.

Catherine V. Laiosa, MS, Huafeng Xie, MS, Min Ye, PhD, Thomas Graf, PhD

Blood (2004) 104 (11): 225.

https://doi.org/10.1182/blood.V104.11.225.225

Published: 2004

Journal Articles

B Cell Development in the Absence of PU.1.

Min Ye, PhD, Olga Ermaermakova-Cirilli, PhD, Thomas Graf, PhD

Blood (2004) 104 (11): 226.

https://doi.org/10.1182/blood.V104.11.226.226

Published: 2004

NARROW

Sgr-1505 Is a Potent MALT1 Protease Inhibitor with a Potential Best-in-Class Profile

Inhibition of CDC7 with Sgr-2921 in AML Models Results in Enhanced DNA Damage and Anti-Leukemic Activity As Monotherapy and in Combination with Standard of Care Agents

Characterization of Potent Paracaspase MALT1 Inhibitors for Hematological Malignancies

LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML

LSD1 Inhibition Exerts Its Anti-Leukemic Effect By Recommissioning PU.1- and C/Ebpα-Dependent Enhancers in AML

Sox4 Is Required for the Formation and Maintenance of Multipotent Progenitors

The Runx-PU.1 pathway preserves normal and AML/ETO9a leukemic stem cells

C/EBPα is required for development of dendritic cell progenitors

In vivo generation of transplantable human hematopoietic cells from induced pluripotent stem cells

Identification of Sox4 As Key Oncogene in Leukemias with Mutated or Silenced C/EBPα

Runx1 Induced Chromatin Folding of the PU.1 Gene Locus Is Necessary for Adult Long-Term Hematopoietic Stem Cell Maintenance

PU.1 Is a Downstream Target of C/EBPα in Normal Hematopoiesis and Acute Myeloid Leukemia

Increasing C/Ebpα Expression Regulates the Transition of Hematopoietic Stem Cells During Development.

Autoregulation of the Transcription Factor PU.1 Via Its Evolutionarily Conserved Upstream Regulatory Element Is Critical in Adult Mouse Hematopoiesis.

T to Myeloid Lineage Reprogramming by the Synergistic Action of C/EBP and PU.1.

B Cell Development in the Absence of PU.1.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only